331 related articles for article (PubMed ID: 32653608)
21. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
23. Iodoquinazoline-derived VEGFR-2 and EGFR
Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
[TBL] [Abstract][Full Text] [Related]
24. Design, Molecular Docking, Synthesis, Anticancer and Anti-Hyperglycemic Assessments of Thiazolidine-2,4-diones Bearing Sulfonylthiourea Moieties as Potent VEGFR-2 Inhibitors and PPARĪ³ Agonists.
Abdelgawad MA; El-Adl K; El-Hddad SSA; Elhady MM; Saleh NM; Khalifa MM; Khedr F; Alswah M; Nayl AA; Ghoneim MM; Abd El-Sattar NEA
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215339
[TBL] [Abstract][Full Text] [Related]
25. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
Khedr F; Ibrahim MK; Eissa IH; Abulkhair HS; El-Adl K
Arch Pharm (Weinheim); 2021 Nov; 354(11):e2100201. PubMed ID: 34411344
[TBL] [Abstract][Full Text] [Related]
26. Modified Benzoxazole-Based VEGFR-2 Inhibitors and Apoptosis Inducers: Design, Synthesis, and Anti-Proliferative Evaluation.
Elwan A; Abdallah AE; Mahdy HA; Dahab MA; Taghour MS; Elkaeed EB; Mehany ABM; Nabeeh A; Adel M; Alsfouk AA; Elkady H; Eissa IH
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956997
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis, Molecular Docking, and Anticancer Activity of Phthalazine Derivatives as VEGFR-2 Inhibitors.
El-Helby AA; Ayyad RRA; Sakr H; El-Adl K; Ali MM; Khedr F
Arch Pharm (Weinheim); 2017 Dec; 350(12):. PubMed ID: 29131379
[TBL] [Abstract][Full Text] [Related]
28. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
29. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
30. New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies.
Elkady H; Abuelkhir AA; Rashed M; Taghour MS; Dahab MA; Mahdy HA; Elwan A; Al-Ghulikah HA; Elkaeed EB; Ibrahim IM; Husein DZ; Metwaly A; Eissa IH
Comput Biol Chem; 2023 Dec; 107():107958. PubMed ID: 37714080
[TBL] [Abstract][Full Text] [Related]
31. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers.
Alanazi MM; Eissa IH; Alsaif NA; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Elkady H; Elwan A
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1760-1782. PubMed ID: 34340610
[TBL] [Abstract][Full Text] [Related]
32. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2.
Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS
Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors.
Ali IH; Abdel-Mohsen HT; Mounier MM; Abo-Elfadl MT; El Kerdawy AM; Ghannam IAY
Bioorg Chem; 2022 Sep; 126():105883. PubMed ID: 35636123
[TBL] [Abstract][Full Text] [Related]
35. New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and
Al-Sanea MM; Hamdi A; Mohamed AAB; El-Shafey HW; Moustafa M; Elgazar AA; Eldehna WM; Ur Rahman H; Parambi DGT; Elbargisy RM; Selim S; Bukhari SNA; Magdy Hendawy O; Tawfik SS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166036. PubMed ID: 36691927
[TBL] [Abstract][Full Text] [Related]
36. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
[TBL] [Abstract][Full Text] [Related]
37. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and anticancer evaluation of N-sulfonylpiperidines as potential VEGFR-2 inhibitors, apoptotic inducers.
Elgammal WE; Halawa AH; Eissa IH; Elkady H; Metwaly AM; Hassan SM; El-Agrody AM
Bioorg Chem; 2024 Apr; 145():107157. PubMed ID: 38340473
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis, in silico ADMET, docking, and antiproliferative evaluations of [1,2,4]triazolo[4,3-c]quinazolines as classical DNA intercalators.
Alesawy MS; Ibrahim MK; Eissa IH; El-Adl K
Arch Pharm (Weinheim); 2022 Apr; 355(4):e2100412. PubMed ID: 35014084
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]